Wire Stories

Category Added in a WPeMatico Campaign

Horizon_Logo_Full-Color_RGB_Registered_Logo

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed enrollment of its Phase 3 clinical trial (OPTIC-J)...